This week MHRP and collaborators at the Institute for HIV Research, University Duisburg-Essen launched a longitudinal cohort study in Germany to evaluate the incidence of HIV subtype B among an at-risk subpopulation and determine the feasibility of conducting an HIV vaccine efficacy trial there in the future.
